Condition
Sjögrens Disease
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06293365Phase 2Active Not RecruitingPrimary
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06531395Phase 2TerminatedPrimary
A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
Showing all 2 trials